Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00236093 · ClinicalTrials.gov registry record · Phase 2
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
A Phase 2 study, sponsored by Cephalon.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00236093 is a Phase 2 study that has completed, run by Cephalon.
The verdict
NCT00236093, a Phase 2 study, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The objective of the study is to monitor the safety (adverse event data) of longer-term use of ACTIQ (Oral Transmucosal Fentanyl Citrate \[OTFC\]) treatment in children with pain associated with cancer, sickle cell disease, or severe burns and breakthrough pain (BTP) who are receiving around the clock (ATC) opioid therapy.
Interventions
- DRUG ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])
Trial Details
| Field | Value |
|---|---|
| Start Date | 2006-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00236093
The ClinicalTrials.gov registry entry for NCT00236093 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) is the first listed.
NCT00236093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00236093 about?
NCT00236093 is a clinical study titled "Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain". The objective of the study is to monitor the safety (adverse event data) of longer-term use of ACTIQ (Oral Transmucosal Fentanyl Citrate \[OTFC\]) treatment in children with pain associated with cancer, sickle cell disease, or severe burns and breakthrough pain (BTP) who are receiving around the clo...
What is the current status of trial NCT00236093?
This trial is currently completed. It is a Phase 2 study. The study started on 2006-10.
What interventions are being tested in trial NCT00236093?
The interventions under investigation include: ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) (DRUG).
Who is sponsoring clinical trial NCT00236093?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.